Attached files
file | filename |
---|---|
EXCEL - IDEA: XBRL DOCUMENT - BIOLOGIX HAIR INC. | Financial_Report.xls |
EX-31.1 - EXHIBIT 31.1 - BIOLOGIX HAIR INC. | ex31_1.htm |
EX-32.1 - EXHIBIT 32.1 - BIOLOGIX HAIR INC. | ex32_1.htm |
EX-31.2 - EXHIBIT 31.2 - BIOLOGIX HAIR INC. | ex31_2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] | Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the quarterly period ended May 31, 2012 | |
[ ] | Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 |
For the transition period from __________ to__________ | |
Commission File Number: 333-173359 |
T&G Apothecary, Inc.
(Exact name of registrant as specified in its charter)
Nevada | 27-4588540 |
(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) |
906 Thayer Drive Gahanna, OH 43230 |
(Address of principal executive offices) |
(702) 528-1806 |
(Registrant’s telephone number) |
___________________________ |
(Former name, former address and former fiscal year, if changed since last report) |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [X] Yes [ ] No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [ ] Yes [X] No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
[ ] Large accelerated filer | [ ] Accelerated filer |
[ ] Non-accelerated filer | [X] Smaller reporting company |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [X] Yes [ ] No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 8,000,000 as of May 31, 2012
1 |
TABLE OF CONTENTS | ||
Page | ||
PART I – FINANCIAL INFORMATION | ||
Item 1: | Condensed Financial Statements | 3 |
Item 2: | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 4 |
Item 3: | Quantitative and Qualitative Disclosures About Market Risk | 6 |
Item 4: | Controls and Procedures | 6 |
PART II – OTHER INFORMATION | ||
Item 1: | Legal Proceedings | 7 |
Item 1A: | Risk Factors | 7 |
Item 2: | Unregistered Sales of Equity Securities and Use of Proceeds | 7 |
Item 3: | Defaults Upon Senior Securities | 7 |
Item 4: | Mine Safety Disclosures | 7 |
Item 5: | Other Information | 7 |
Item 6: | Exhibits | 7 |
2 |
PART I - FINANCIAL INFORMATION
Item 1. Condensed Financial Statements
Our condensed financial statements included in this Form 10-Q are as follows:
These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended May 31, 2012 are not necessarily indicative of the results that can be expected for the full year.
3 |
T & G APOTHECARY, INC.
(A Development Stage Company)
ASSETS | ||||||||||||
May 31, | February 29, | |||||||||||
2012 | 2012 | |||||||||||
CURRENT ASSETS | (unaudited) | |||||||||||
Cash | $ | 92 | $ | 92 | ||||||||
Prepaid expenses | — | — | ||||||||||
Total Current Assets | 92 | 92 | ||||||||||
TOTAL ASSETS | $ | 92 | $ | 92 | ||||||||
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||
CURRENT LIABILITIES | ||||||||||||
Accounts payable | $ | 22,206 | $ | 21,478 | ||||||||
Note payable - related party | 27,704 | 21,164 | ||||||||||
Accrued interest payable - related party | 2,525 | 2,059 | ||||||||||
Total Current Liabilities | 52,435 | 44,701 | ||||||||||
STOCKHOLDERS' DEFICIT | ||||||||||||
Common stock, 100,000,000 shares authorized at par value of $0.001; 8,000,000 shares issued and outstanding | 8,000 | 8,000 | ||||||||||
Additional paid-in capital | (5,000 | ) | (5,000 | ) | ||||||||
Deficit accumulated during the development stage | (55,343 | ) | (47,609 | ) | ||||||||
Total Stockholders' Deficit | (52,343 | ) | (44,609 | ) | ||||||||
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ | 92 | $ | 92 |
The accompanying notes are an integral part of these condensed financial statements.
F-4 |
T & G APOTHECARY, INC.
(A Development Stage Company)
Condensed Statements of Operations
From Inception | From Inception | |||||||||||
For the Three | on January 18, | on January 18, | ||||||||||
Months Ended | 2011 Through | 2011 Through | ||||||||||
May 31, | May 31, | May 31, | ||||||||||
2012 | 2011 | 2012 | ||||||||||
REVENUES | $ | — | $ | — | $ | — | ||||||
OPERATING EXPENSES | ||||||||||||
General and administrative | — | 75 | 4,959 | |||||||||
Professional fees | 7,268 | 9,160 | 47,860 | |||||||||
Total Operating Expenses | 7,268 | 9,235 | 52,819 | |||||||||
LOSS FROM OPERATIONS | (7,268 | ) | (9,235 | ) | (52,819 | ) | ||||||
OTHER EXPENSES | ||||||||||||
Interest expense | (466 | ) | (156 | ) | (2,524 | ) | ||||||
Total Other Expenses | (466 | ) | (156 | ) | (2,524 | ) | ||||||
PROVISION FOR INCOME TAXES | — | — | — | |||||||||
NET LOSS | $ | (7,734 | ) | $ | (9,391 | ) | $ | (55,343 | ) | |||
BASIC AND DILUTED: | ||||||||||||
LOSS PER SHARE | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.00 | ) | |||
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | 8,000,000 | 8,000,000 |
The accompanying notes are an integral part of these condensed financial statements
F-5 |
T & G APOTHECARY, INC.
(A Development Stage Company)
Condensed Statements of Cash Flows
From Inception | From Inception | |||||||||||
For the Three | on January 18, | on January 18, | ||||||||||
Months Ended | 2011 Through | 2011 Through | ||||||||||
May 31, | May 31, | May 31, | ||||||||||
2012 | 2011 | 2012 | ||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||||||
Net loss | $ | (7,734 | ) | (9,391 | ) | $ | (55,343 | ) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||
Expenses paid on Company's behalf by a related party | 6,540 | — | 9,329 | |||||||||
Changes to operating assets and liabilities: | ||||||||||||
Prepaid expenses | — | 7,302 | — | |||||||||
Accounts payable | 728 | 348 | 22,206 | |||||||||
Accrued interest - related party | 466 | 156 | 2,525 | |||||||||
Net Cash Used in Operating Activities | — | (1,585 | ) | (21,283 | ) | |||||||
CASH FLOWS FROM INVESTING ACTIVITIES | — | — | — | |||||||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||||||
Common stock issued for cash | — | — | 3,000 | |||||||||
Proceeds from note payable - related party | — | — | 18,375 | |||||||||
Net Cash Provided by Financing Activities | — | — | 21,375 | |||||||||
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | — | (1,585 | ) | 92 | ||||||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 92 | 2,474 | — | |||||||||
CASH AND CASH EQUIVALENTS AT END OF PERIOD | $ | 92 | $ | 889 | $ | 92 | ||||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ||||||||||||
CASH PAID FOR: | ||||||||||||
Interest | $ | — | $ | — | ||||||||
Income Taxes | $ | — | $ | — |
The accompanying notes are an integral part of these condensed financial statements.
F-6 |
NOTE 1 - CONDENSED FINANCIAL STATEMENTS
The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at May 31, 2012, and for all periods presented herein have been made.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's February 29, 2012 audited financial statements. The results of operations for the periods ended May 31, 2012 and May 31, 2011, are not necessarily indicative of the operating results for the full year.
NOTE 2 - GOING CONCERN
The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.
In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from management and significant shareholders sufficient to meet its minimal operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.
The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES
Basis of Accounting
The Company’s financial statements are prepared using the accrual method of accounting. The Company has elected a February 28 fiscal year-end.
F-7 |
NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Recent Accounting Pronouncements
The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements.
Reclassification
Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation.
NOTE 4 - NOTES PAYABLE RELATED PARTY
On January 19, 2011 the Company entered into a Promissory Note Agreement whereby the Company received $18,475 from a related party. The note accrues interest at a rate of 10.0% per annum, is unsecured and is due on demand. As of May 31, 2012, a related party paid expenses on behalf of the Company in the amount of $9,329. This amount bears no interest and is due on demand. As of May 31, 2012 and 2011, the Company had accrued interest payable of $2,525 and $2,059, respectively.
NOTE 5 – COMMON STOCK
The Company is authorized to issue 100,000,000 common shares at a par value of $0.001 per share. At May 31, 2012, the Company had issued and outstanding 8,000,000 shares of common stock. Of the issued and outstanding stock, 5,000,000 shares were issued to the founder of the company as founder shares. On February 7, 2011, the Company issued 3,000,000 shares of its par value $0.001 common stock for $3,000 cash.
NOTE 6 – SUBSEQUENT EVENTS
In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no material subsequent events to report.
F-8 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.
Company Overview
We intend to develop, market and sell five initial products under our women’s care line. We will not manufacture our products in-house; instead we intend to source the work to Sensibility Soaps, a company we feel is well equip to handle our manufacturing needs. We have not entered into any contracts or agreements with Sensibility Soaps.
We expect to complete product development and be in a position to start manufacturing our products by the summer or fall of 2012. During this period, we will be working closely with the chemist at Sensibility Soaps upon his recommendation to modify some of the formulas in order to maintain the ability to refer to our products as “organic.” We have learned that some of the ingredients in our original formulas may cause skin irritation on some consumers. There was also brought to our attention a concern about product shelf life. In order to address these concerns, we are testing our formulations at Sensibility Soaps’ facility. The cost for this research will be approximately $1,275.
While the modifications to the formulas are being done, we will also be working closely with Whip-Smart on the packaging that will be used for the products. We will not be able to finalize the containers until the testing is completed on the products. One of the tests that will be performed is to determine whether the product can be placed in a transparent container or if it will need to be placed in a container where no light can penetrate to the product.
While the modifications to the formulas are being done, we will also be working closely with Whip-Smart on the packaging that will be used for the products. We have not entered into any contracts or agreements with Whip-Smart Development. We will not be able to finalize the containers until the testing is completed on the products. One of the tests that will be performed is to determine whether the product can be placed in a transparent container or if it will need to be placed in a container where no light can penetrate to the product.
After the complete packaging has been approved, Whip-Smart will begin production of the initial quantities we have determined will give us a good indication of how the products will be received in the market. This step of the process should be completed by approximately the summer or fall of 2012 and will cost us approximately $16,750 (making 10,000 initial bottles and designs for the 5 products).
4 |
When our final products and packaging have been completed, the completed products will be sent to Sensibility Soaps with instructions to fill the containers with the initial sampling of our five final products. Once all samples have been approved, we will begin the production of the first batch of all 5 of our products. We anticipate that the production of our first batch of all five of our products will commence by the summer of 2012. The cost to complete sampling and produce our first batch of 5 products will be approximately $150,000 (~$3 per product per bottle for 5 products of 10,000 bottles each).
Results of Operations for the Three Months Ended May 31, 2012 and 2011 and Period from January 18, 2011 (Date of Inception) to May 31, 2012
We generated no revenue for the period from January 18, 2011 (Date of Inception) until May 31, 2012. Our Operating Expenses during three months ended May 31, 2012 were $7,268 compared to $9,235 during the same period ended 2011, consisting of mainly professional fees along with organizational costs and bank charges. We incurred operating expenses of $52,819 for the period from January 18, 2011 (Date of Inception) to May 31, 2012. We, therefore, recorded a net loss of $7,734 for the three months ended May 31, 2012, as compared with $9,391 for the same period ended May 31, 2011, and $55,343 for the period from January 18, 2011 (Date of Inception) until May 31, 2012.
We anticipate our operating expenses will increase as we implement our business plan. The increase will be attributable to expenses to implement our business plan, and the professional fees to be incurred in connection with our ongoing operating expenses as a reporting company under the Securities Exchange Act of 1934.
Liquidity and Capital Resources
As of May 31, 2012, we had total current assets of $92. We had current liabilities of $52,435 as of May 31, 2012. Thus, we have a working capital deficit of ($52,343) as of May 31, 2012.
Operating activities used $21,283 in cash for the period from January 18, 2011 (Date of Inception) until May 31, 2012. Our net loss of $55,343 represented all of our negative operating cash flow offset by an increase in accounts payable of $22,206 and related party accrued interest of $2,525. Financing activities during the period from January 18, 2011 (Date of Inception) to May 31, 2012 generated $21,375 in cash during the period.
On January 19, 2011 we entered into a Promissory Note Agreement whereby we received $18,375 from our officer and director, Ms. Johnson. The note accrues interest at a rate of 10.0% per annum, is unsecured and is due on demand. As of May 31, 2012, we had accrued interest payable of $2,525. Additionally, $9,229 in Company expenses were paid by a Company shareholder on the Company’s behalf. This amount accrues no interest and is payable on demand.
As of May 31, 2012, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.
As described above, our estimated cost to bring the products to the completion and available for sale is approximately $200,000. For this substantial amount of money, we plan to get bank financing with the local relationships we have in place potentially with Huntington National Bank & Fifth Third Banks. We also plan to access our network of potential investors, and possibly use broker dealers to assist fund the continuation of operations and get the first batch of products completed.
Off Balance Sheet Arrangements
As of May 31, 2012, there were no off balance sheet arrangements.
5 |
Going Concern
Our financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. We have not yet established an ongoing source of revenues sufficient to cover our operating costs and allow us to continue as a going concern. Our ability to continue as a going concern is dependent on our obtaining adequate capital to fund operating losses until we become profitable. If we are unable to obtain adequate capital, we could be forced to cease operations.
In order to continue as a going concern, we will need, among other things, additional capital resources. Management's plan is to obtain such resources for us by obtaining capital from management and significant shareholders sufficient to meet our minimal operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that we will be successful in accomplishing any of our plans.
Our ability to continue as a going concern is dependent upon our ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern..
Item 3. Quantitative and Qualitative Disclosures About Market Risk
A smaller reporting company is not required to provide the information required by this Item.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of May 31, 2012. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, Carolyne Johnson. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of May 31, 2012, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of May 31, 2012, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.
Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting
Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending February 28, 2013: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.
6 |
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the three months ended May 31, 2012 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.
A smaller reporting company is not required to provide the information required by this Item.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None
Item 3. Defaults upon Senior Securities
None
Item 4. Mine Safety Disclosures
Not applicable.
None
Exhibit Number | Description of Exhibit |
31.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
101** | The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended May 31, 2012 formatted in Extensible Business Reporting Language (XBRL). |
**Provided herewith
7 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
T&G Apothecary, Inc.
Date: July 23, 2012
By: /s/ Carolyne Johnson
Carolyne Johnson
Title: Chief Executive Officer and Director
8 |